TXG
NASDAQ10x Genomics Inc.
Price$72.38+2.03 (+2.89%)
01:30 PM07:45 PM
News · 26 weeks56-44%
2026-04-192026-10-11
Mix3290d
- Insider13(41%)
- Other9(28%)
- SEC Filings5(16%)
- Analyst3(9%)
- Earnings2(6%)
Latest news
25 items- PR10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026PLEASANTON, Calif., Oct. 13, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will report financial results for the third quarter ended September 30, 2026 after market close on Thursday, November 5, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.Live audio of the webcast will be available on the "
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
- PR10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood CancersMulti-project collaboration with Fred Hutch Cancer Center spans biomarker discovery in bladder cancer and a single cell approach to residual disease detection in acute myeloid leukemiaPLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a multi-project research collaboration with Fred Hutchinson Cancer Center (Fred Hutch), one of the nation's leading cancer research institutions, to advance the use of single cell and spatial technologies in both solid tumor and hematologic malignancies.The collaboration marks 10x's first clinical research initiative to e
- PR10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental ConclusionsSentira Spatial Analysis leverages NVIDIA accelerated computing to cut spatial data processing times from hours to minutes, putting rapid, iterative analysis at the fingertips of every researcherPLEASANTON, Calif., Sept. 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life science technology leader focused on accelerating science and advancing human health, today announced Sentira, a new cloud analysis platform that extends the 10x experience from data generation to experimental conclusions, beginning with Sentira Spatial Analysis. For more than a decade, 10x has pioneered technologies that catalyzed the single cell and spatial biology revolutions, changing how researchers meas
- PR10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' HandsExtraordinary early global demand, ambitious new research programs and an expansive technology roadmap mark the beginning of a new era for biological understandingPLEASANTON, Calif., Sept. 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the first commercial shipments of Atera, marking a major milestone for a platform that will redefine what's possible in spatial biology. Introduced in April of this year, Atera brings together whole transcriptome analysis, sub-cellular resolution, single cell sensitivity and u
- ANALYSTArgus initiated coverage on 10x Genomics with a new price targetArgus initiated coverage of 10x Genomics with a rating of Buy and set a new price target of $110.00
- INSIDERDirector Suliman Shehnaaz sold $464,668 worth of shares (5,723 units at $81.19) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 23,792 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERChief Executive Officer Saxonov Serge sold $2,030,562 worth of shares (25,000 units at $81.22) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,050,249 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- SECSEC Form 144 filed by 10x Genomics Inc.144 - 10x Genomics, Inc. (0001770787) (Subject)
- INSIDERChief Financial Officer Taich Adam sold $2,995,470 worth of shares (46,388 units at $64.57) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 316,344 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- PRLunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research10x Genomics, a leader in single-cell and spatial biology, to combine its spatial biology technologies with Lunit's AI-powered H&E pathology analysis to advance oncology biomarker discoverySEOUL, South Korea, Sept. 10, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 10x Genomics, Inc. (NASDAQ:TXG) will incorporate Lunit's AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow. Lunit SCOPE IO will be used to analyze Hematoxylin and Eosin (H&E) pathology images alongside spatial molecular data generated from 10x's oncology-focused clinical research studies.
- ANALYSTUBS resumed coverage on 10x Genomics with a new price targetUBS resumed coverage of 10x Genomics with a rating of Neutral and set a new price target of $68.00
- INSIDERDirector Stuelpnagel John R sold $1,235,072 worth of shares (20,000 units at $61.75), decreasing direct ownership by 6% to 328,436 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- SECSEC Form SCHEDULE 13G filed by 10x Genomics Inc.SCHEDULE 13G - 10x Genomics, Inc. (0001770787) (Subject)
- INSIDERChief Executive Officer Saxonov Serge gifted 100 shares, decreasing direct ownership by 0.01% to 1,075,249 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- SECSEC Form 144 filed by 10x Genomics Inc.144 - 10x Genomics, Inc. (0001770787) (Subject)
- ANALYSTRBC Capital Mkts initiated coverage on 10x Genomics with a new price targetRBC Capital Mkts initiated coverage of 10x Genomics with a rating of Sector Perform and set a new price target of $70.00
- INSIDERChief Executive Officer Saxonov Serge sold $667,901 worth of shares (10,486 units at $63.69) as part of a pre-agreed trading plan, decreasing direct ownership by 0.97% to 1,075,349 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- PR10x Genomics Wins Patent Infringement Verdict Against Parse BiosciencesJury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challengePLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (NYSE:QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025. The patents are exclusively licensed from Roche Sequencing Solutions. The jury also rejected Parse's challenges to the validity of the patents, finding al
- INSIDERChief Executive Officer Saxonov Serge sold $1,168,775 worth of shares (18,545 units at $63.02), decreasing direct ownership by 2% to 1,085,835 units (SEC Form 4) to satisfy tax liability4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERChief Financial Officer Taich Adam sold $1,081,853 worth of shares (17,166 units at $63.02), decreasing direct ownership by 5% to 362,732 units (SEC Form 4) to cover withholding tax4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDEROfficer Hindson Benjamin J. sold $870,860 worth of shares (13,818 units at $63.02), decreasing direct ownership by 3% to 488,182 units (SEC Form 4) (withholding obligation)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERDirector Suliman Shehnaaz sold $140,478 worth of shares (2,207 units at $63.65) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 29,515 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- SECSEC Form 144 filed by 10x Genomics Inc.144 - 10x Genomics, Inc. (0001770787) (Subject)
- INSIDERChief Executive Officer Saxonov Serge gifted 4,000 shares, decreasing direct ownership by 0.36% to 1,104,380 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
TXG FAQ
7 questionsWhat does 10x Genomics Inc. do?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their...Where does TXG stock trade?
10x Genomics Inc. (TXG) is listed on NASDAQ.What sector and industry is TXG in?
10x Genomics Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.When did 10x Genomics Inc. go public?
10x Genomics Inc. (TXG) completed its IPO in 2019.What are analysts saying about TXG?
10x Genomics Inc. has had 8 recent analyst actions on file. The most recent action was from Argus: Buy on 2026-09-28. Recent price targets range from $1200.00 to $2000.00.What companies are similar to TXG?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare TXG side-by-side with any of them on Quantisnow.How can I track TXG on Quantisnow?
Quantisnow aggregates 10x Genomics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TXG to receive live email and push alerts on every new disclosure.